Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M A Martin de Bustamante

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
What are the Key Driving Factors Behind RSA Decisions In Australia?P Nash, M A Martin de Bustamante
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Time to Reimbursement for Oncology Agents from EMA Marketing Authorization to AIFA Approval AS "C(NN)" Class versus. AIFA Approval AS "A" or "H" ClassL Monoson, M A Martin de Bustamante, R Beckerman
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Modelling the Impact of Persistence Improvements with an Electronic Injection Device on Escalation to 2nd Line Treatment in Patients with Relapsing Remitting Multiple Sclerosis (RRMS)D M Meletiche, T Rutkowski, M A Martin de Bustamante, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
What are the Key Driving Factors Behind RSA Decisions In Australia?P Nash, M A Martin de Bustamante
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Time to Reimbursement for Oncology Agents from EMA Marketing Authorization to AIFA Approval AS "C(NN)" Class versus. AIFA Approval AS "A" or "H" ClassL Monoson, M A Martin de Bustamante, R Beckerman
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Modelling the Impact of Persistence Improvements with an Electronic Injection Device on Escalation to 2nd Line Treatment in Patients with Relapsing Remitting Multiple Sclerosis (RRMS)D M Meletiche, T Rutkowski, M A Martin de Bustamante, et al.
Pageof 1